Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

August 1, 2010

Primary Completion Date

January 3, 2013

Study Completion Date

January 3, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

25 mg oral lenalidomide once daily on Days 1-21 every 28 days

DRUG

Dexamethasone

Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22

Trial Locations (13)

100071

307 Hospital of Chinese PLA, Beijing

100081

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

200003

Shanghai Changzheng Hospital, Shanghai

200233

Shanghai 6th People's Hospital, Shanghai

200433

Changhai Hospital, Shanghai

215006

The First Affiliated Hospital of Soochow University, Suzhou

300200

Chinese PLA General Hospital, Beijing

310003

The First Hospital Affiliated of College Medicine, Zhejiang University, Hangzhou

310009

The First Hospital Affiliated of College Medicine, Zhejiang University, Hangzhou

410008

Xiangya Hospital of Central- South University, Changsha

510080

Guangdong General Hospital, Guangzhou

510515

Nanfang Hospital of Southern Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01593410 - Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter